keyword
MENU ▼
Read by QxMD icon Read
search

Cancer breast cancer oncology

keyword
https://www.readbyqxmd.com/read/28432979/the-reality-of-economics-for-oncologists
#1
REVIEW
David Taylor
This article outlines the historical development of health economics and its present role in oncology related health technology assessments (HTAs). Despite concerns about the prices and immediate costs of new anticancer medicines for indications such as breast cancer overall spending on such treatments is affordable and offers long term value for money in countries such as the US, Canada and those of Western Europe. Oncologists wishing to protect the interests of current and future patients with both advanced and earlier stage cancers may be regarded as having a responsibility to understand the nature of health economic evaluations, and to be actively involved in decisions affecting access to current treatments and future levels of investment in incrementally improving therapies...
April 19, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28429422/retrospective-evaluation-of-premenopausal-hormone-sensitive-breast-cancer-patients-treated-with-adjuvant-gonadotropin-releasing-hormone-analogue-anatolian-society-of-medical-oncology-asmo-study
#2
Ayşe Demirci, Necati Alkış, Faysal Dane, Ayşe Durnalı, Ömer Kamil Yazıcı, Rashad Rzayev, Serap Kaya, Doğan Yazılıtaş, Mevlüde İnanç, Melike Özçelik, Tülay Akman, Mehmet Ali Kaplan, Yusuf Günaydın, Arife Ulaş, Özlem Sönmez, Saadet Tokluoğlu, Gamze Gököz Doğu, Öznur Bal, Mahmut Gümüş
AIM: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. METHODS: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. RESULTS: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1-87) months...
April 21, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28428642/-technology-and-prevention-in-the-era-of-mobile-health-applications-for-cancer-screening-programs
#3
Fabrizio Bert, Maria Rosaria Gualano, Salvatore Clemente, Giulia Villa, Roberta Siliquini
The Italian national health system provides screening to detect breast, colorecatal and cervical cancers, however, population adherence is not as high as expected. Smartphones and their applications (apps) could be used as a tool to communicate with the population and to help improve adherence. The aim of this study was to analyze the features and functions of smartphone applications aimed at secondary prevention of oncological diseases. In February 2016, we reviewed online app stores, using specific key-words, to search for available apps for cancer screening...
January 2017: Igiene e Sanità Pubblica
https://www.readbyqxmd.com/read/28428099/nipple-sparing-mastectomy-and-its-application-on-brca-gene-mutation-carrier
#4
REVIEW
Michael Co, Rosemarie Chiu, Tung Milly Chiu, Yau Chun Chong, Swan Lau, Yung Ho Lee, Hoi Man To, Ava Kwong
In breast cancer 1 (BRCA) gene mutation carriers, mastectomy is still the mainstay of treatment for breast cancers due to the increased risk of local recurrence. It is performed as a therapeutic, as well as prophylactic procedure. However, mastectomy with removal of nipple areolar complex (NAC) is associated with adverse cosmetic outcome. NAC sparing mastectomy (NSM), which results in better cosmetic outcome, has been performed in non-BRCA mutation carriers. While studies have shown that NSM is a oncologically safe in sporadic breast cancers, its application in BRCA mutation carriers is still controversial...
February 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28426105/the-prevalence-and-clinical-relevance-of-tumor-infiltrating-lymphocytes-tils-in-ductal-carcinoma-in-situ-of-the-breast
#5
G Pruneri, M Lazzeroni, V Bagnardi, G B Tiburzio, N Rotmensz, A DeCensi, A Guerrieri-Gonzaga, A Vingiani, G Curigliano, S Zurrida, F Bassi, R Salgado, G Van den Eynden, S Loi, C Denkert, B Bonanni, G Viale
Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast cancer, but their clinical role in ductal carcinoma in situ (DCIS) has not been ascertained. Patients and methods: We evaluated the prevalence and clinical relevance of TILs in a well annotated series of 1488 consecutive DCIS women with a median follow-up of 8.2 years. Detailed criteria for TILs evaluation were pre-defined involving the International Immuno-Oncology Biomarker Working Group...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28423789/using-electronic-health-records-to-assess-depression-and-cancer-comorbidities
#6
Miguel A Mayer, Alba Gutierrez-Sacristan, Angela Leis, Santiago De La Peña, Ferran Sanz, Laura I Furlong
Comorbid diseases are an important concern in oncology since they can affect the choice and effectiveness of treatment. What is particularly relevant is the fact that the diagnosis of depression in cancer patients has an important impact on the quality of life of these patients. Although there is no consensus about a specific relationship of depression with certain cancer types, some authors have proposed that depression constitutes a risk factor for cancer. The objective of this study is to identify the presence of comorbidities in a massive EHR system, between depression and the 10 most common cancers in women and men and to determine if there is a preferred temporal ordering in the co-occurrence of these diseases...
2017: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/28418819/cancer-genomics-and-important-oncologic-mutations-a-contemporary-guide-for-body-imagers
#7
REVIEW
Veronica L Cox, Priya Bhosale, Gauri R Varadhachary, Nicolaus Wagner-Bartak, Isabella C Glitza, Kathryn A Gold, Johnique T Atkins, Pamela T Soliman, David S Hong, Aliya Qayyum
The field of cancer genomics is rapidly evolving and has led to the development of new therapies. Knowledge of commonly involved cellular pathways and genetic mutations is now essential for radiologists reading oncology cases. Radiogenomics is an emerging area of research that seeks to correlate imaging features with cancer genotypes. Such knowledge may extend the utility of multiparametric imaging to yield information regarding cancer prognosis and likelihood of therapeutic response. To date, only a handful of radiogenomics studies have been performed to evaluate solid tumors of the body, and there is much to explore...
May 2017: Radiology
https://www.readbyqxmd.com/read/28414115/cost-analysis-of-a-surgical-consensus-guideline-in-breast-conserving-surgery
#8
Jennifer Yu, Leisha C Elmore, Amy E Cyr, Rebecca L Aft, William E Gillanders, Julie A Margenthaler
BACKGROUND: The SSO/ASTRO consensus statement was the first professional guideline in breast oncology to declare "no ink on tumor" as a negative margin in patients with stages I/II breast cancer undergoing breast conservation therapy (BCT). We sought to analyze the financial impact of this guideline at our institution using a historic cohort. STUDY DESIGN: We identified women undergoing re-excision following breast-conserving surgery for invasive breast cancer from 2010-2013 using a prospectively-maintained institutional database...
April 14, 2017: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/28408840/clinical-course-and-outcome-of-patients-with-high-level-microsatellite-instability-cancers-in-a-real-life-setting-a-retrospective-analysis
#9
Naama Halpern, Yael Goldberg, Luna Kadouri, Morasha Duvdevani, Tamar Hamburger, Tamar Peretz, Ayala Hubert
BACKGROUND: The prognostic and predictive significance of the high-level microsatellite instability (MSI-H) phenotype in various malignancies is unclear. We describe the characteristics, clinical course, and outcomes of patients with MSI-H malignancies treated in a real-life hospital setting. PATIENTS AND METHODS: A retrospective analysis of MSI-H cancer patient files was conducted. We analyzed the genetic data, clinical characteristics, and oncological treatments, including chemotherapy and surgical interventions...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28408621/endocrine-therapy-initiation-and-medical-oncologist-utilization-among-women-diagnosed-with-ductal-carcinoma-in-situ
#10
Chelsea Anderson, Anne Marie Meyer, Stephanie B Wheeler, Lei Zhou, Katherine E Reeder-Hayes, Hazel B Nichols
BACKGROUND: Though randomized clinical trials have demonstrated a reduction in second breast events with endocrine therapy among women with ductal carcinoma in situ (DCIS), use of these therapies remains highly variable. The purpose of this study was to evaluate patient and treatment-related factors associated with endocrine therapy initiation and medical oncology specialty utilization after DCIS. MATERIALS AND METHODS: We identified women with a DCIS diagnosis during 2006-2010 in the North Carolina Central Cancer Registry with linked public and private insurance claims in the University of North Carolina Integrated Cancer Information Surveillance System data resource...
April 13, 2017: Oncologist
https://www.readbyqxmd.com/read/28398847/traceback-a-proposed-framework-to-increase-identification-and-genetic-counseling-of-brca1-and-brca2-mutation-carriers-through-family-based-outreach
#11
Goli Samimi, Marcus Q Bernardini, Lawrence C Brody, Charlisse F Caga-Anan, Ian G Campbell, Georgia Chenevix-Trench, Fergus J Couch, Michael Dean, Joanne A de Hullu, Susan M Domchek, Ronny Drapkin, Heather Spencer Feigelson, Michael Friedlander, Mia M Gaudet, Marline G Harmsen, Karen Hurley, Paul A James, Janice S Kwon, Felicitas Lacbawan, Stephanie Lheureux, Phuong L Mai, Leah E Mechanic, Lori M Minasian, Evan R Myers, Mark E Robson, Susan J Ramus, Lisa F Rezende, Patricia A Shaw, Thomas P Slavin, Elizabeth M Swisher, Masataka Takenaka, David D Bowtell, Mark E Sherman
In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer. The concept, designated Traceback, was prompted by the recognition that although BRCA1 and BRCA2 mutations are frequent in women with ovarian cancer, many such women have not been tested, especially if their diagnosis predated changes in testing guidelines...
April 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28398846/anthracyclines-in-early-breast-cancer-the-abc-trials-usor-06-090-nsabp-b-46-i-usor-07132-and-nsabp-b-49-nrg-oncology
#12
Joanne L Blum, Patrick J Flynn, Greg Yothers, Lina Asmar, Charles E Geyer, Samuel A Jacobs, Nicholas J Robert, Judith O Hopkins, Joyce A O'Shaughnessy, Chau T Dang, Henry Leonidas Gómez, Louis Fehrenbacher, Svetislava J Vukelja, Alan P Lyss, Devchand Paul, Adam M Brufsky, Jong-Hyeon Jeong, Linda H Colangelo, Sandra M Swain, Eleftherios P Mamounas, Stephen E Jones, Norman Wolmark
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab...
April 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28398024/gonadotropin-releasing-hormone-analogues-for-the-prevention-of-chemotherapy-induced-premature-ovarian-failure-in-breast-cancer-patients
#13
Benedetta Conte, Lucia Del Mastro
Since the survival of patients with cancer has significantly improved, chemotherapy-related premature ovarian failure (POF) in young cancer survivors has become a major issue in oncology. POF is associated with several health-related negative consequences, including menopausal symptoms, increased risk of cardiovascular diseases, osteoporosis, sexual disfunction, and infertility1-5. According to the major international guidelines, embryo/oocyte cryopreservation are the standard procedures for fertility preservation in young cancer women6,7...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28397505/-current-recommendations-for-the-prevention-and-treatment-of-venous-thromboembolism-in-cancer-patients
#14
J Halámková, M Penka
About 20% of patients suffer from venous thromboembolism (VTE) during oncology disease. Active cancer, along with cancer therapy, increases the risk of VTE, especially in the first 6 months after diagnosis. Most often VTE accompanies haematological malignancies and CNS tumours, and gastrointestinal, breast, lung, ovary and uterine cancer. The presence of distant metastases, together with the implantation of a central venous catheter, increases the risk even more. A cancer patient also has a 2-5× higher risk of recurrence of VTE during anticoagulant therapy than patients without a malignancy, as well as a 2-6× higher risk of serious bleeding...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28395768/what-constitutes-an-unmet-medical-need-in-oncology-an-empirical-evaluation-of-author-usage-in-the-biomedical-literature
#15
Eric Lu, Joseph Shatzel, Florence Shin, Vinay Prasad
The phrase "unmet medical need" has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an "unmet medical need." We queried Google Scholar to identify publications where authors used the phrase "unmet medical need" to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28393991/-quality-of-life-in-chilean-breast-cancer-survivors
#16
M Elisa Irarrázaval, Pascale Kleinman, Fernando Silva R, Loreto Fernández González, Camilo Torres, Marcela Fritis, Carolina Barriga, Herman Waintrub
BACKGROUND: Quality of Life (QOL) assessment may evaluate the impact of diseases and their treatment on the overall well-being of patients. AIM: To assess QOL in Chilean breast cancer survivors. PATIENTS AND METHODS: Ninety one female breast cancer patients aged 60 ± 10 years, who finished their oncologic treatment at least a year prior to the assessment, who were disease free and in medical follow-up were included in the study. They completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire and the breast cancer module QLQ-BR23...
December 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28391295/diagnosis-and-treatment-of-brain-metastases-from-solid-tumors-guidelines-from-the-european-association-of-neuro-oncology-eano
#17
Riccardo Soffietti, Ufuk Abacioglu, Brigitta Baumert, Stephanie E Combs, Sara Kinhult, Johan M Kros, Christine Marosi, Philippe Metellus, Alexander Radbruch, Salvador S Villa Freixa, Michael Brada, Carmine M Carapella, Matthias Preusser, Emilie Le Rhun, Roberta Rudà, Joerg C Tonn, Damien C Weber, Michael Weller
The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, the European Association of Neuro-Oncology (EANO) created a multidisciplinary Task Force to draw evidence-based guidelines for patients with brain metastases from solid tumors. Here, we present these guidelines, which provide a consensus review of evidence and recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic factors, and different treatment options...
February 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28382802/major-clinical-research-advances-in-gynecologic-cancer-in-2016-10-year-special-edition
#18
REVIEW
Dong Hoon Suh, Miseon Kim, Kidong Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS)...
May 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28382641/differences-in-fatigue-severity-in-a-sample-of-adult-cancer-patients
#19
Cindy S Tofthagen, Xusheng Chen, Elsa Pedro, Leorey N Saligan, Velda J Gonzalez
OBJECTIVE: To describe differences in fatigue severity in a sample of adult Puerto Rican patients during and post cancer treatments. BACKGROUND: Hispanics, including Puerto Ricans, are an understudied population who are underrepresented in clinical trials, especially in symptom research. Although symptom management is a clinical priority in oncology care, treatment-related differences in Puerto Rican cancer patients' report of fatigue severity has not been well described...
April 5, 2017: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/28382097/oncologic-outcomes-after-immediate-breast-reconstruction-following-total-mastectomy-in-patients-with-breast-cancer-a-matched-case-control-study
#20
Jai Min Ryu, Hyun-June Paik, Sungmin Park, Ha Woo Yi, Seok Jin Nam, Seok Won Kim, Se Kyung Lee, Jonghan Yu, Soo Youn Bae, Jeong Eon Lee
PURPOSE: The use of immediate breast reconstruction (IBR) following total mastectomy (TM) has increased markedly in patients with breast cancer. As the indications for IBR have been broadened and more breast-conserving surgery-eligible patients are undergoing IBR, comparing the oncologic safety between TM only and IBR following TM becomes more difficult. This study aimed to analyze the oncologic outcomes between TM only and IBR following TM via a matched case-control methodology. METHODS: A retrospective review was conducted to identify all patients who underwent TM between 2008 and 2014...
March 2017: Journal of Breast Cancer
keyword
keyword
7548
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"